Patrick F. Williams Appointed Chief Financial Officer of STAAR Surgical
July 06 2020 - 7:00AM
Business Wire
Deborah Andrews to Remain in Advisory Role
During Transition
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses and companion
delivery systems for the eye, today announced that Patrick F.
Williams has joined the Company as Chief Financial Officer
effective today. Mr. Williams is reporting to Caren Mason,
President and Chief Executive Officer. His appointment is part of a
planned transition following Deborah Andrews’ previously announced
retirement. Ms. Andrews will continue in an advisory role to ensure
a smooth transition of duties to Mr. Williams.
“STAAR is pleased to have a financial leader of Patrick’s
caliber join the team at a time of such significant global
opportunity for our EVO family of lenses,” said Caren Mason,
President and CEO of STAAR Surgical. “Patrick has an impressive
record of success in executive leadership roles in medical device.
His financial and operational experience in leading consumer-facing
and marketing focused medical device companies makes him well
suited to join STAAR. He has demonstrated a track record of success
in significantly growing revenue and shareholder value.”
Mr. Williams joins STAAR with over 20 years of financial and
operational management experience with public companies. Mr.
Williams was most recently at Sientra, Inc., where he initially
served as the Chief Financial Officer before transitioning to the
General Manager of the miraDry® business unit. Prior to Sientra,
Mr. Williams was Chief Financial Officer of ZELTIQ Aesthetics,
Inc., a publicly-traded medical device company that was acquired in
2017. Mr. Williams has also served as Vice President at NuVasive,
Inc., a San Diego-based medical device company, in strategy,
finance and investor relations roles.
Mr. Williams stated, “I am incredibly excited to join STAAR. The
Company has a unique opportunity to accelerate an already
impressive growth trajectory and become the refractive procedure of
choice for ophthalmic surgeons and patients around the world. I
look forward to working with Caren, the STAAR team and applying my
experience and deep understanding in building growth medical device
companies to accomplish this goal.”
Ms. Mason continued, “I thank Deborah for continuing to work
with STAAR in an advisory role to ensure a smooth transition of
responsibilities to Patrick. She is leaving behind a strong global
finance and accounting team and we are grateful for all her
contributions to STAAR over a 25-year career. We wish Deborah a
wonderful retirement and all the best in her future endeavors.”
Mr. Williams received an MBA in Finance and Management from San
Diego State University and a Bachelor of Arts in Economics from the
University of California, San Diego.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 30 years, designs, develops, manufactures and markets
implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses.
All of these lenses are foldable, which permits the surgeon to
insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or
“ICL”, which includes the EVO Visian ICL™ product line. More than
1,000,000 Visian® ICLs have been implanted to date and STAAR
markets these lenses in over 75 countries. To learn more about the
ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200706005064/en/
Investors & Media Brian Moore Vice President,
Investor, Media Relations and Corporate Development (626) 303-7902,
Ext. 3023 bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Mar 2024 to Apr 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Apr 2023 to Apr 2024